Highest-materiality recent filing
KORU Medical amends bylaws to give shareholders exclusive director-removal authority
Board unanimously adopted Amendment No. 1 to Section 3.05 of Amended and Restated By-laws effective August 13, 2026.
KORU Medical Q2 revenue $12.0M (+18% YoY), net income $0.25M, raises gross margin guidance to 62-64%
Net revenues $12.0M (+18% YoY); gross profit $7.8M (+20%); gross margin 65.1% vs 63.5% prior year.
Amendment extends initial term to Dec 31, 2031, with auto-renewal unless 180-day non-renewal notice given.
KORU Medical shareholders approve all proposals at 2026 annual meeting
All seven director nominees elected with over 97% of votes cast.
KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated
Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.
KORU Medical amends HSBC credit facility, extends maturities and lowers rate floor
Amendment extends $5M revolver maturity from Dec 31, 2026 to Mar 30, 2028.
CEO Linda Tharby to retire June 2026; Adam Kalbermatten named successor
Tharby retires as CEO effective June 30, 2026; will serve as advisory employee through Dec 31, 2026.
KORU Medical reports 22% FY2025 revenue growth; positive adjusted EBITDA; initiates FY2026 guidance
Q4 2025 net revenue $10.9M (+23% YoY); FY2025 net revenue $41.1M (+22% YoY).
KORU Medical amends bylaws to enhance stockholder nomination procedures
Board unanimously adopted amended bylaws effective Feb 5, 2026.
Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.
KORU Medical restates manufacturing/supply pact with Command Medical through 2026
Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, effective Jan 1, 2024.
KORU Medical Q3 revenue $10.4M (+27% YoY), raises full-year guidance
Q3 net revenues $10.4M, up 27% YoY; core business (domestic + international) $9.8M, up 30%.
KORU Medical Q2 revenue up 21% to record $10.2M; raises FY 2025 revenue guidance
Q2 2025 net revenue of $10.2 million, +21% YoY; Core revenue $9.3M (+19%), PST $0.9M (+42%).
KORU Medical Systems shareholders elect all director nominees at 2025 annual meeting
All seven nominees elected; votes 'for' ranged from 23.5M to 23.9M of 23.95M cast (excl. broker non-votes).
KORU Medical reports record Q1 revenue of $9.6M, up 18% YoY; raises FY2025 guidance
Core revenue (Domestic + International) grew 21% YoY to $9.4M; International up 35.6%.
KORU Medical CCO resigns; FY2025 revenue guidance reiterated at $38-39M
Kenneth Miller resigned as Chief Commercial Officer effective April 3, 2025, to become CEO at a non-competing firm.
KORU Medical amends loan agreement, extends credit facility maturity to Dec 2026
Amendment extends $5M revolving credit facility maturity to Dec 31, 2026; term loan interest-only period to Oct 1, 2026.
KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M
Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).
KORU Medical reports record Q4 revenue $8.9M (+23% YoY); positive cash flow in Q4
Preliminary full-year 2024 net revenue of $33.7M, up 18% YoY; Q4 revenue $8.9M, up 23% YoY.
KORU Medical Q3 revenue $8.2M (+17% YoY); raises FY 2024 guidance
Q3 net revenue $8.2M, up 17% YoY; gross margin 63.4%, up 140 bps from 62.0%.
KORU Medical Systems adopts LTIP; grants up to 434,489 PSUs plus RSUs and options to execs
LTIP approved; equity awards granted to CEO Tharby (63,872 RSUs, 127,660 PSUs, 140,950 options) and other named execs.
KORU Medical Q2 revenue record $8.4M, up 22%; raises FY2024 guidance
Q2 net revenues of $8.4M, a 22% YoY increase; core business grew 20% driven by SCIg market growth and share gains.
KORU Medical appoints Christopher Pazdan as COO, eliminates CTO role held by Brian Case
Christopher Pazdan appointed Chief Operating Officer, effective July 18, 2024, from SVP Operations.
Koru Medical dismisses MMQ as auditor, engages Cherry Bekaert
Audit Committee dismissed McGrail Merkel Quinn & Associates (MMQ) effective June 3, 2024.
Koru Medical Systems reports 2024 annual meeting results; all proposals passed
Elected all 7 director nominees: Fletcher, Cascella, French, Manko, Matin, Tharby, Wholihan.
KORU Medical Q1 revenue up 11% to $8.2M; gross margin expands 620bps to 62.3%
Net revenues of $8.2M, +10.9% YoY; Core business grew 13.6%, driven by 63% International increase.
KORU Medical wins EU notified body appeal, CE certification continues uninterrupted
BSI had recommended against continued certification after March 2024 audit nonconformance.
KORU Medical reports Q4 rev $7.2M, FY net loss $13.7M; guides 2024 rev $31.2-32.2M
Q4 net revenues $7.2M (-2% YoY); gross margin improved to 60.3% (+470bps).
KORU Medical Q3 revenue down 9.8% YoY; cuts full-year guidance to $28.0-$28.5M
Q3 net revenue $7.0M (-9.8% YoY); net loss $1.4M ($0.03/share) vs $1.2M loss prior year.
KORU Medical appoints Edward Wholihan to Board of Directors effective September 28, 2023
Edward Wholihan appointed to fill Board vacancy on Sept 28, 2023; brings over 25 years CFO experience in life sciences and healthcare.
KORU Medical Q2 revenue $6.9M (+6% YoY); cuts FY2023 revenue guidance to $31.0-32.5M
Q2 net revenue $6.9M (+6% YoY); Domestic Core +8%, International Core +17%.
KORU Medical Q2 prelim revenue $6.9M (+6% YoY); cuts FY2023 guidance to $31-32.5M; CFO resigns
Q2 2023 preliminary net revenue ~$6.9M, up 6% YoY; Domestic Core +8%, International Core +17%, Novel Therapies -28%.
KORU Medical appoints Andrew LaFrence as CFO, effective July 10, 2023
Andrew LaFrence brings 39 years of finance/accounting experience; previously CFO at Vyant Bio and Surmodics, 26 years at KPMG.
KORU Medical reincorporates in Delaware, files $71.25M shelf registration
Reincorporation effective May 16, 2023; each NY share converted to one DE share; business unchanged.
KORU Medical Q1 revenue $7.4M (+18% YoY); reaffirms FY2023 guidance
Q1 net revenue $7.4M, up 18% YoY; net loss $2.4M ($0.05 diluted) vs $2.5M loss prior year.
KORU Medical reports 19% revenue growth in 2022, guides 17-20% growth for 2023
Q4 2022 revenue $7.34M (+13.2% YoY); FY2022 revenue $27.9M (+18.8% YoY).
KORU Medical Q3 revenue up 28.5% to $7.8M; raises FY2022 guidance to $27.5-28.0M
Net sales $7.76M (+28.5% YoY); domestic core +16.2%, international core +46.8%, novel therapies +251.9%.
KORU Medical Q2 net sales up 18.4% to $6.5M; raises FY revenue guidance but lowers margin forecast
Net sales $6.5M (+18.4% YoY) driven by novel therapies (NRE milestone) and core growth; backorders $0.3M.
KORU Medical modifies $3.5M credit line; extends maturity to June 2023, changes interest rate
Entered Loan Modification Extension Agreement with KeyBank National Association on June 29, 2022.
KORU Medical Systems completes legal name change from Repro Med Systems Inc.
Name changed to KORU Medical Systems, Inc. effective June 22, 2022 after shareholder approval on May 6, 2022.
Repro Med CFO Karen Fisher to resign June 30, 2022; Tom Adams named interim CFO
CFO Karen Fisher resigns effective June 30, 2022; no disagreements with company.
Shareholders approve name change to Koru Medical Systems, Inc. and Delaware reincorporation
All 6 proposals at 2022 annual meeting passed by wide margins.
KORU Medical Q1 net sales up 15% to $6.2M, net loss widens to $2.5M, raises FY22 revenue guidance
Net sales $6.24M (+15% YoY); domestic core up 13.2%, novel therapies $0.36M (including NRE).
KORU Medical Q4 revenue up 60% to $6.5M, but full-year net loss widens to $4.6M
Q4 net revenues $6.5M (+60% YoY); adjusted growth 27.6% excluding prior-year inventory stocking.
KORU Medical expects FY2021 revenue $23.0M-$23.2M; Q4 to show sequential growth
Q4 2021 expected to be the fourth consecutive quarter of positive sequential revenue growth.
KORU Medical to unveil updated strategic plan at investor day on Dec 9, 2021
Management to present updated strategic plan via webcast on Thursday, Dec 9, 2021 at 10:00 AM EST.
KORU Medical Q3 net loss $1.1M; revenue $6.0M, 9% sequential growth
Net revenue $6.0M, 9% sequential growth; adjusted net revenue up 9% YoY excluding prior year inventory stocking.
KORU Medical Q2 net revenue $5.5M; net loss $1.1M; sequential growth of 2%
Net revenue of $5.5 million, down 28.3% YoY but up 2% sequentially.
On April 3, 2025, Kenneth Miller resigned his employment and position as Chief Commercial Officer of KORU Medical Systems, Inc. (the “Company”), effective immediately, to pursue a Chief Executive Officer role at an organization that does not compete with the Company.
On July 18, 2024, the Company’s Board of Directors eliminated the position of Chief Technology Officer, currently held by Brian Case, effective as of September 16, 2024. Mr. Case’s employment with the Company will terminate concurrently with elimination of that position.
Kenneth Miller, age 55, has been appointed by KORU Medical Systems, Inc. (the “Company”) to serve in the newly created position of Chief Commercial Officer commencing November 6, 2023.
On September 28, 2023, Edward Wholihan was appointed to the Board of Directors (the “Board”) of KORU Medical Systems, Inc. (the “Company”), filling the existing vacancy on the Board.
On and effective as of July 27, 2023, Andrew D. C. LaFrence, the Company’s Chief Financial Officer, resigned his employment for personal and family reasons.
On and effective as of August 1, 2023, Thomas Adams, the Company’s Vice President of Financial Planning and Analysis and formerly interim Chief Financial Officer, was appointed as the Company’s Chief Financial Officer.
Thomas Adams, Interim Chief Financial Officer, will continue as the Company’s Vice President of Financial Planning and Analysis upon the appointment of Mr. LaFrence.
Andrew D. C. LaFrence has been employed by KORU Medical Systems, Inc. (the “Company”) to serve as its Chief Financial Officer commencing July 10, 2023.
In the interim, the Company’s Vice President of Financial Planning and Analysis, Tom Adams, will serve as Interim Chief Financial Officer of the Company effective July 1, 2022.
As reported under Item 1.01 above, Karen Fisher, the Company’s Chief Financial Officer, will resign her employment effective as of June 30, 2022 to pursue other opportunities.
Max materiality 0.80 · Median 0.60 · Most common event earnings